OncoMatch/Clinical Trials/NCT07073365
Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)
Is NCT07073365 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for non-small cell lung cancer.
This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Required: EGFR l858r
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — first-line
Completion of four cycles of first-line osimertinib plus platinum-based chemotherapy (FLAURA2 regimen)
Must have received: platinum-based chemotherapy — first-line
Completion of four cycles of first-line osimertinib plus platinum-based chemotherapy (FLAURA2 regimen)
Lab requirements
Blood counts
adequate organ function based on institutional laboratory criteria
Kidney function
adequate organ function based on institutional laboratory criteria
Liver function
adequate organ function based on institutional laboratory criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify